FDA oversight limited on off-label promotion
A new GAO report finds the FDA incapable of reviewing all drug advertising -- including the identification of off-label promotions -- due to the quantity of submissions and the variety of materials.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.